Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 13 / Drugs : 11 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathway : 1

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Aceneuramic acid
   Suzuki Ryoichi
      2021   Phase 3   JPRN-jRCT2021200030   -
   ULTRAGENYX PHARMACEUTICAL INC.
      2017   Phase 3   EUCTR2016-000360-42-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom
Aceneuramic acid extended-release
   Ultragenyx Pharmaceutical Inc
      2016   Phase 2   NCT02731690   Bulgaria;Canada;United States
      2015   Phase 3   NCT02377921   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
Aceneuramic acid extended-release tablets
   Ultragenyx Pharmaceutical Inc
      2016   Phase 3   NCT02736188   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
Common name: sialic acid
   ULTRAGENYX PHARMACEUTICAL INC.
      2017   Phase 3   EUCTR2016-000360-42-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 3   EUCTR2016-000360-42-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000360-42-GB   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
Deflazacort
   Ludwig-Maximilians - University of Munich
      2003   Phase 2/Phase 3   NCT00527228   Germany
INN: aceneuramic acid
   ULTRAGENYX PHARMACEUTICAL INC.
      2015   Phase 3   EUCTR2014-005432-33-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 3   EUCTR2016-000360-42-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004553-41-BG   Bulgaria;Canada;United States
      2016   Phase 3   EUCTR2016-000360-42-GB   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005432-33-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
N-acetylneuraminic acid
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 2   EUCTR2015-004553-41-BG   Bulgaria;Canada;United States
NPC-09
   Nobelpharma
      2021   Phase 3   NCT04671472   Japan
   Suzuki Ryoichi
      2021   Phase 3   JPRN-jRCT2021200030   -
   Tohoku University
      2010   Phase 1   NCT01236898   Japan
Sialic acid
   ULTRAGENYX PHARMACEUTICAL INC.
      2015   Phase 3   EUCTR2014-005432-33-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 2   EUCTR2015-004553-41-BG   Bulgaria;Canada;United States
      2016   Phase 3   EUCTR2014-005432-33-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
Sialic acid, N-acetylneuraminic acid
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 3   EUCTR2016-000360-42-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
UX001
   ULTRAGENYX PHARMACEUTICAL INC.
      2017   Phase 3   EUCTR2016-000360-42-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom
      2015   Phase 3   EUCTR2014-005432-33-IT   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2017   Phase 3   EUCTR2016-000360-42-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004553-41-BG   Bulgaria;Canada;United States
      2016   Phase 3   EUCTR2016-000360-42-GB   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005432-33-BG   Bulgaria;Canada;France;Israel;Italy;United Kingdom;United States